<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1439">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04498247</url>
  </required_header>
  <id_info>
    <org_study_id>V591-001</org_study_id>
    <secondary_id>2020-003493-46</secondary_id>
    <secondary_id>V591-001</secondary_id>
    <nct_id>NCT04498247</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)</brief_title>
  <official_title>A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this early Phase 1 study is to identify the V591 dose that achieves
      the target immune response in humans based on preclinical or early clinical data.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2020</start_date>
  <completion_date type="Anticipated">April 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with at Least 1 Solicited Injection Site Adverse Event</measure>
    <time_frame>Up to ~5 days after vaccination</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with at Least 1 Solicited Systemic Adverse Event</measure>
    <time_frame>Up to ~14 days after vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with at Least 1 Unsolicited Adverse Event</measure>
    <time_frame>Up to ~28 days after vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with at Least 1 Serious Adverse Event</measure>
    <time_frame>Up to ~365 days (±14 days) after vaccination</time_frame>
    <description>A serious adverse event is &quot;life threatening,&quot; requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity and is a congenital anomaly/birth defect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Discontinued Study Treatment due to an Adverse Event</measure>
    <time_frame>Up to ~365 days (±7 days) after vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with at Least 1 Medically Attended Adverse Event</measure>
    <time_frame>Up to ~365 days (±14 days) after vaccination</time_frame>
    <description>A medically attended adverse event (MAAE) is an AE in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency room visit, office visit, or an urgent care visit with any medical personnel for any reason.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for Serum Neutralizing Antibodies (nAb) as Measured by Plaque Reduction Neutralization Test (PRNT): All Panels</measure>
    <time_frame>Day 29</time_frame>
    <description>Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Total Anti-Spike Immunoglobulin G (IgG) Antibodies as Measured by Enzyme-Linked Immunosorbent Assay (ELISA): All Panels</measure>
    <time_frame>Day 29</time_frame>
    <description>Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for Serum Neutralizing Antibodies as Measured by PRNT: Panels A,B, I and J</measure>
    <time_frame>Day 85</time_frame>
    <description>Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA: Panels A,B, I and J</measure>
    <time_frame>Day 85</time_frame>
    <description>Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for Serum Neutralizing Antibodies as Measured by PRNT: Panels K and L</measure>
    <time_frame>Day 197</time_frame>
    <description>Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA: Panels K and L</measure>
    <time_frame>Day 197</time_frame>
    <description>Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for Serum nAb as Measured by PRNT</measure>
    <time_frame>Panels C-E and G-H: Days 1, 15, 29, 57, 85, 115, 211, and 365; Panels A,B, I and J: Days 1, 15, 29, 57, 71, 85, 115, 211, and 422; Panels F, K and L: Days 1, 15, 29, 85, 169, 197, 365 and 534</time_frame>
    <description>Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA</measure>
    <time_frame>Panels C-E and G-H: Days 1, 15, 29, 57, 85, 115, 211, and 365; Panels A,B, I and J: Days 1, 15, 29, 57, 71, 85, 115, 211, and 422; Panels F, K and L: Days 1, 15, 29, 85, 169, 197, 365 and 534</time_frame>
    <description>Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Coronavirus Disease (COVID-19)</condition>
  <arm_group>
    <arm_group_label>Part 1: Panels A, B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this 18 to 55 year old sentinel cohort will receive 2 doses (Day 1 and Day 57) of V591 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: Panels C-E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this 18 to 55 year old cohort will receive 1 dose (Day 1) of V591 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: Panel F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this 18 to 55 year old cohort will receive 2 doses (Day 1 and Day 169) of V591 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2B: Panels G, H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this &gt;55 year old cohort will receive 1 dose (Day 1) of V591 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2B: Panels I, J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this &gt;55 year old cohort will receive 2 doses (Day 1 and Day 57) of V591 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2B: Panels K, L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this &gt;55 year old cohort will receive 2 doses (Day 1 and Day 169) of V591 or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V591</intervention_name>
    <description>1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.</description>
    <arm_group_label>Part 1: Panels A, B</arm_group_label>
    <arm_group_label>Part 2A: Panel F</arm_group_label>
    <arm_group_label>Part 2A: Panels C-E</arm_group_label>
    <arm_group_label>Part 2B: Panels G, H</arm_group_label>
    <arm_group_label>Part 2B: Panels I, J</arm_group_label>
    <arm_group_label>Part 2B: Panels K, L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (0.9% sodium chloride) administered via IM injection.</description>
    <arm_group_label>Part 1: Panels A, B</arm_group_label>
    <arm_group_label>Part 2A: Panel F</arm_group_label>
    <arm_group_label>Part 2A: Panels C-E</arm_group_label>
    <arm_group_label>Part 2B: Panels G, H</arm_group_label>
    <arm_group_label>Part 2B: Panels I, J</arm_group_label>
    <arm_group_label>Part 2B: Panels K, L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is in overall good health based on medical history, physical examination,
             electrocardiogram (ECG) and vital sign (VS) measurements performed prior to
             randomization.

          -  Is in overall good health based on laboratory safety tests obtained at the screening
             visit.

          -  Has a body mass index (BMI) ≤30 kg/m2 inclusive (after rounding to the nearest whole
             number).

          -  Has been practicing social distancing for at least two weeks prior to planned Day 1
             vaccination and has no close contacts with known active severe acute respiratory
             syndrome coronavirus (SARS-CoV)-2 infection in that time period.

          -  Sentinel trial participants ONLY (Panel A, Panel B, and the first 5 participants of
             Panel E): Seronegative for SARS-COV-2.

          -  Is male or female, from 18 years to 55 years of age (inclusive) (Parts 1 and 2A) or
             &gt;55 years of age (Part 2B), at the time of providing documented informed consent.

          -  Male participants are eligible to participate if they agree to refrain from donating
             sperm during the intervention period and for at least 6 months after the last dose of
             study intervention, be abstinent from heterosexual intercourse as their preferred and
             usual lifestyle and agree to remain abstinent OR agree to use contraception unless
             confirmed to be azoospermic .

          -  Contraceptive use by men and women should be consistent with local regulations
             regarding the methods of contraception for those participating in clinical studies.

          -  A female participant is eligible to participate if she is not pregnant or
             breastfeeding, is not a woman of childbearing potential (WOCBP) or Is a WOCBP and
             using an acceptable contraceptive method or be abstinent from heterosexual intercourse
             as their preferred and usual lifestyle.

          -  A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as
             required by local regulations) before the first dose of study intervention. If a urine
             test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy
             test is required. In such cases, the participant must be excluded from participation
             if the serum pregnancy result is positive.

          -  Refrain from donating oocyte during the intervention period and for at least 6 months
             after the last dose of study intervention.

          -  The investigator is responsible for review of medical history, menstrual history, and
             recent sexual activity to decrease the risk for inclusion of a woman with an early
             undetected pregnancy.

          -  The participant (or legally acceptable representative) has provided documented
             informed consent/assent for the study, including for future biomedical research.

          -  Is willing to comply with the study restrictions, including social distancing between
             screening and randomization.

          -  Is willing to abstain from donating whole blood or blood derivatives, tissue or organ
             all along the study.

          -  Agrees to provide study personnel with a primary telephone number as well as an
             alternate means of contact, if available (such as an alternate telephone number or
             email) for follow-up purposes.

          -  Can read, understand, and complete the Vaccination Report Card.

        Exclusion Criteria

          -  Is currently actively infected with SARS-CoV-2 (confirmed by polymerase chain
             reaction;[PCR]).

          -  Has prior medical history of confirmed SARS-CoV-2 infection or known exposure to an
             individual with confirmed coronavirus disease 2019 (COVID-19) disease or SARS CoV-2
             infection within the past 2 weeks. With the exception of the sentinel participants
             (Panel A, Panel B, and the first 5 participants of Panel E), study participants will
             not be screened for enrollment by SARS-CoV-2 serology, allowing those who may have had
             a prior asymptomatic SARS-CoV-2 infection to be enrolled.

          -  Has a history of severe adverse reactions to vaccine administration, including
             anaphylaxis and related symptoms, such as urticaria, respiratory difficulty,
             angioedema and abdominal pain to vaccines, or history of known or suspected allergic
             reaction likely to be exacerbated by any component of the COVID-19 vaccine.

          -  Is currently (or highly suspected to be) immunocompromised, including anticipating the
             need for systemic immunosuppressive treatment within the next 6 months or 12 months
             for 2-dose Day 1, Day 169 panels or has been diagnosed or highly suspected as having a
             congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic
             lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA),
             inflammatory bowel disease, or other autoimmune condition that could impact the immune
             response or the safety of the study vaccine.

          -  Has clinically significant thrombocytopenia or other coagulation disorder
             contraindicating intramuscular vaccination or repeated venipuncture.

          -  Has history or current evidence of any condition, therapy, laboratory abnormality, or
             other circumstance that might expose the participant to risk by participating in the
             study, confound the results of the study or interfere with the participant's
             participation for the full duration of the study.

          -  Has a history or presence of clinically significant pulmonary disorders (e.g. chronic
             obstructive pulmonary disease [COPD], etc.), or asthma.

          -  Has a history of confirmed SARS-CoV-1 or Middle Eastern respiratory syndrome (MERS)

          -  Has a history of or current clinically significant medical condition that puts or may
             put a participant at increased risk for severe SARS-CoV-2 disease, such as conditions
             associated with increased risk of severe illness from COVID-19, cancer, chronic kidney
             disease, COPD, immunocompromised state (weakened immune system) from solid organ
             transplant, obesity (BMI of 30 or higher), serious heart conditions, such as heart
             failure, coronary artery disease, or cardiomyopathies, sickle cell disease, Type 2
             diabetes mellitus, asthma, cerebrovascular disease, cystic fibrosis, hypertension or
             high blood pressure, an immunocompromised state (weakened immune system), neurologic
             conditions, such as dementia, liver disease, pregnancy, pulmonary fibrosis (having
             damaged or scarred lung tissues), smoking, thalassemia (a type of blood disorder), or
             Type 1 diabetes mellitus.

          -  Part 2B ONLY: Older adult participants having mild, well controlled hypertension as is
             widely characteristic of aging are allowed if their medication regimens have not
             substantively changed for the past 6 months, hypertension has not led to
             hospitalization or currently increased rate of clinic visits over the past year, and
             hypertension has not been confirmed as putting subjects at increased risk of severe
             illness from COVID-19 by the CDC
             (https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-ris
             k.html).

          -  Is mentally or legally incapacitated, has significant emotional problems at the time
             of pre-study (screening) visit or expected during the conduct of the study or has a
             history of clinically significant psychiatric disorder of the last 5 years.

          -  Has a history of any clinically significant major neurological disorders or seizures
             (including Guillain-Barré syndrome), with the exception of febrile seizures during
             childhood.

          -  Has a history of cancer (malignancy)

          -  Has a known or suspected history of significant multiple and/or severe allergies
             (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant
             intolerability (i.e., systemic allergic reaction) to prescription or non-prescription
             drugs or food.

          -  Is positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human
             immunodeficiency virus (HIV)-1 or 2 antibodies. Individuals with antibodies to
             hepatitis C may be enrolled if hepatitis C viral load is undetectable and there is no
             evidence of or history of liver disease.

          -  Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4
             weeks prior to the pre-study (screening) visit.

          -  Has received immunosuppressive drugs (like e.g. systemic corticosteroids, excluding
             topical preparations and inhalers) within 3 months prior to the first vaccination or 6
             months for chemotherapies.

          -  *Has received vaccination within 4 weeks prior to first vaccination or is planning to
             receive a licensed vaccine 4 weeks before or after each study vaccination (e.g.

        Inactivated influenza vaccine).

          -  *Has received measles-containing vaccine within 3 months prior to the first
             vaccination.

          -  Has received a blood transfusion or blood products, including immunoglobulin, starting
             from 3 months before the first study vaccination or is scheduled to receive a blood
             transfusion or blood product through study completion. Autologous blood transfusions
             are not considered an exclusion criterion.

          -  Is unable to meet the concomitant medication restrictions

          -  Is using antiviral medications or any investigational agents for prophylaxis of
             SARSCoV-2 within 4 weeks prior to the first vaccination.

          -  Has ever participated in an investigational study of a SARS-CoV-2 vaccine, or an
             antiviral or other biologic product intended for the treatment of COVID-19.

          -  Has participated in another vaccine study within 3 months prior to screening or has
             participated in an investigational study within 4 weeks prior to the pre-study
             (screening) visit.

          -  Has glycated hemoglobin (A1C) ≥ 6.5% at screening.

          -  Has a history of alcohol, cocaine, or opioid abuse during the previous 3 years.

          -  Participants who currently smoke or used nicotine or nicotine-containing products
             (e.g. nicotine patch) within last 3 months. Former smokers that have less than a 10
             pack-year history of smoking and have not smoked in the last 12 months are eligible to
             be enrolled.

          -  Has a tattoo, scar or other physical finding at the area of the vaccination site that
             would interfere with intramuscular injection or a local tolerability assessment.

          -  Presents any concern by the investigator regarding safe participation in the study or
             for any other reason the investigator considers the participant inappropriate for
             participation in the study.

          -  Lives in a nursing home or long-term care facility.

          -  Is currently working in occupations with high risk of exposure to SARS-CoV-2 (e.g.,
             health care worker with direct patient contact, emergency response personnel), or, at
             the investigator's discretion to be at increased risk to acquire SARS-CoV-2 for any
             other reason.

          -  Individuals who are living and/or working with severely immunocompromised people,
             pregnant women, lactating women, children under 12 months old, or any other individual
             that, in the judgment of the investigator, might be at increased risk.

          -  Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or
             child) who is investigatively involved with this study.

               -  if the participant meets these exclusion criteria, the Day 1 Visit may be
                  rescheduled for a time when these criteria are not met.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Centers of America, LLC ( Site 0014)</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>954-990-7649</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC ( Site 0013)</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>316-462-0420</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc. ( Site 0011)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>859-264-8999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research PC ( Site 0012)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>816-943-0770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SCRI-CCCIT GesmbH ( Site 0006)</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0043 5 7255 25800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Wien ( Site 0007)</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>004314016038290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent ( Site 0003)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3293320050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SGS Life Science Services ( Site 0001)</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3232172560</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ATC - Clinical Pharmacology Unit ( Site 0002)</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3243668306</phone>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

